SURVYR

LNAI

Lunai Bioworks Inc.
$0.29
−$0.18 (37.23%)Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-97%-56%-16%+25%+66%Oct 2025Oct 2026Apr 202652w high $13.2852w low $0.23
LNAISPY
Wall St. Highest PT $15.23 (+5062.7%) Wall St. Avg PT $12.48 (+4130.5%)
$0$5$11$16$21POC $2Hi $15Avg $12
Underwater Drawdown %Max DD -97.5%Current -97.5%
0.0%-97.5%
Relative Strength vs SPY-111.3% vs SPYUnderperforming
+128%0%-128%
1W
−$0.39 (56.62%)
1M
−$1.85 (86.21%)
3M
−$2.03 (87.34%)
6M
−$2.19 (88.10%)
YTD
−$6.76 (95.82%)
1Y
−$8.02 (96.45%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for LNAI
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.3M
52-week range$0.23 – $13.28
Dividend yieldNo dividend

What they do

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for LNAI yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

LNAI earningsNext report in 15 days
Next report
Thu Nov 12, 2026Time not confirmed
EPS consensus–
Revenue consensus$0
Source: Yahoo Finance · refreshed 2026-10-25 14:53:56 ET
No EPS history available.

Quarterly revenue

QuarterRevenueYoY
2026-06-30$31.1K–
2026-03-31$20.9K–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister
PR Newswire · Oct 22

Stats refreshed 2026-10-25 14:53:56 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026